ライフサイエンスコーパス: oxcarbazepine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 primidone to 34.3 per 1000 person-years for oxcarbazepine.

2 7-1.09]), topiramate (0.86 [0.72-1.03]), and oxcarbazepine (0.92 [0.73-1.18]).

3 ad a non-significant advantage compared with oxcarbazepine (1.15 [0.86-1.54]).

4 compared with placebo [adjusted mean change: oxcarbazepine, -10.90 (N=55); placebo, -9.79 (N=55)].

5 Oxcarbazepine, a keto-analogue of carbamazepine, was rec

6 e of psychiatric adverse events for both the oxcarbazepine and placebo groups was higher than that re

7 sts that the use of gabapentin, lamotrigine, oxcarbazepine, and tiagabine, compared with the use of t

8 antiepileptic drugs, such as carbamazepine, oxcarbazepine, and topiramate, enhances hepatic cytochro

9 ch as valproate, lamotrigine, carbamazepine, oxcarbazepine, antipsychotics, electroconvulsive therapy

10 Lamotrigine, gabapentin, topiramate, and oxcarbazepine are available for use as monotherapy in ma

11 Because carbamazepine and oxcarbazepine can enhance the sensitivity of renal tubul

12 Understanding the mechanisms by which oxcarbazepine can lead to a reduction of serum sodium le

13 cts titrated over 3 weeks to a maximum daily oxcarbazepine dose of 2,400mg.

14 er an acute water-load test performed before oxcarbazepine exposure and after maintenance on the medi

15 Before oxcarbazepine exposure, the percentage of water load exc

16 Eleven patients (19%) in the oxcarbazepine group discontinued the study because of ad

17 ported in at least 5% of the patients in the oxcarbazepine group with an incidence at least twice tha

18 with low bioavailability and solubility (eg, oxcarbazepine) had the greatest variability in BE.

19 , lamotrigine (HR, 1.84; 95% CI, 1.43-2.37), oxcarbazepine (HR, 2.07; 95% CI, 1.52-2.80), tiagabine (

20 er trial examined the efficacy and safety of oxcarbazepine in the treatment of bipolar disorder in ch

21 These findings indicate that oxcarbazepine-induced hyponatremia is not attributable t

22 Oxcarbazepine is not significantly superior to placebo i

23 he water load, suggesting that the effect of oxcarbazepine is physiological.

24 ouble-blinded, flexibly dosed treatment with oxcarbazepine (maximum dose 900-2400 mg/day) or placebo.

25 Oxcarbazepine (mean dose=1515 mg/day) did not significan

26 and new chemical C-H oxidation methods using oxcarbazepine, naproxen, and an early compound hit (phth

27 ssible mechanisms include a direct effect of oxcarbazepine on the renal collecting tubules or an enha

28 eive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

29 eive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

30 Carbamazepine (CBZ) and oxcarbazepine (OXC) are widely used anticonvulsants that

31 Some patients treated with oxcarbazepine showed the development of hyponatremia, wh

32 After the intake of oxcarbazepine, the water load resulted in a reduction of

33 Carbamazepine and oxcarbazepine were not immunosuppressive in lymphocyte-d

34 he sodium channel blockers carbamazepine and oxcarbazepine, which although effective are associated w

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。